GSK today revealed plans for its Stevenage site where it wants to turn its 92-acre research & development site into one of Europe’s largest clusters for biotechnology start-ups and other early-stage life sciences companies, creating up to 5,000 new jobs.
Britain’s second-biggest drugmaker is looking to sell 33 acres of land and attract up to £400m investment from a developer to build out the campus, over the next five to 10 years.
GSK’s Stevenage site is one of its two global R&D hubs, and is already home to the UK’s largest cell and gene therapy cluster, the third largest globally. If successful, the new campus could attract several world-class research organisations to Stevenage.
The new campus would sit next to GSK’s existing research centre at Stevenage and the company hopes that work on a master plan could begin next year.
Tony Wood, senior vice president of medicinal science & technology at GSK said: The past 18 months has shown the UK life sciences sector at its best and the UK has recently unveiled an ambitious 10-year vision for the UK life sciences sector. Our goal is for Stevenage to emerge as a top destination for medical and scientific research by the end of the decade. We are excited to find a development partner to realise our vision to foster the next generation of world-class scientists and biotechnology firms in Britain.”